Clinical Trials Logo

Anaplastic Thyroid Cancer clinical trials

View clinical trials related to Anaplastic Thyroid Cancer.

Filter by:

NCT ID: NCT06374602 Recruiting - Clinical trials for Anaplastic Thyroid Cancer

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Start date: March 25, 2024
Phase: Phase 2
Study type: Interventional

This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints.

NCT ID: NCT06362694 Recruiting - Clinical trials for Anaplastic Thyroid Cancer

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

Start date: March 25, 2024
Phase: Phase 2
Study type: Interventional

This pilot phase 2 study evaluates the effectiveness and safety of the Rechallenge concept in patients with BRAF-positive anaplastic thyroid cancer after progression on anti-BRAF therapy. Patients with BRAF-positive anaplastic thyroid cancer who were previously treated with dabrafenib and trametinib (with a clinical or objective response at the start of treatment) and later with tumor progression during anti-BRAF therapy and subsequent lines of chemotherapy are scheduled to undergo targeted therapy (repeated administration of dabrafenib and trametinib in standard doses) and evaluate the outcomes according to the primary and secondary endpoints.

NCT ID: NCT06235216 Not yet recruiting - Clinical trials for Differentiated Thyroid Cancer

Sacituzumab govitEcan in THYroid Cancers

SETHY
Start date: February 2024
Phase: Phase 2
Study type: Interventional

SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC). The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.

NCT ID: NCT06079333 Recruiting - Clinical trials for Anaplastic Thyroid Cancer

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

NEO-ATACT
Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

Anaplastic thyroid cancer (ATC) is an almost invariable lethal cancer in humans. Most patients present with a rapid progressive mass in the neck with progressive complaints like dyspnoea, dysphagia or pain. The risk of suffocation is the main reason for rapid surgical intervention, but we know from literature that an oncological resection with clear margins is seldomly achieved. Some patients deteriorate that fast after surgery that radiation therapy and/or chemotherapy is not feasible anymore. Patients with BRAF-mutated ATC already have shown to benefit from targeted BRAF/MEK inhibition. This study aims to increase the number of patients that undergo a successful R0 tumor resection after neo-adjuvant BRAF/MEK inhibitor treatment.

NCT ID: NCT05819593 Not yet recruiting - Clinical trials for Anaplastic Thyroid Cancer

Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences

Start date: May 2024
Phase:
Study type: Observational

Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in anaplastic thyroid cancer clinical research, as well as the reasons for withdrawal or discontinuation. Insights gained from this study will ultimately benefit those with anaplastic thyroid cancer who may be invited to participate in clinical research in the years to come.

NCT ID: NCT05796960 Recruiting - Thyroid Cancer Clinical Trials

European Multicenter Study on Surgical Management of Advanced Thyroid Cancer

ATCEU
Start date: December 15, 2022
Phase:
Study type: Observational

The main aim of the study is to evaluate peri-operative surgical characteristics, operation extent, postoperative morbidity, and outcomes in patients undergoing surgery for advanced thyroid cancer in different European centers using the EUROCRINE® database.

NCT ID: NCT05696548 Active, not recruiting - Clinical trials for Anaplastic Thyroid Cancer

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Start date: July 2, 2019
Phase: Phase 2
Study type: Interventional

This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.

NCT ID: NCT05102292 Active, not recruiting - Clinical trials for Anaplastic Thyroid Cancer

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Start date: December 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to assess efficacy, safety and PK in anaplastic thyroid cancer (ATC) given HLX208 (BRAF V600E inhibitor).

NCT ID: NCT04579757 Active, not recruiting - Colorectal Cancer Clinical Trials

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Start date: March 5, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).

NCT ID: NCT04574817 Not yet recruiting - Clinical trials for Anaplastic Thyroid Cancer

Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

Start date: December 28, 2020
Phase: Phase 2
Study type: Interventional

There are currently no target therapies approved for treatment of anaplastic thyroid cancer (ATC), leading to a clear need for improving therapy for ATC. This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with metastatic or locally advanced anaplastic thyroid cancer.